A panelist discusses how clinicians choose between sleep aids like dual orexin receptor antagonists (DORAs) and other medications based on patient comorbidities, chronicity of insomnia, and adverse effect profiles, with DORAs offering a safer, long-term solution for patients with chronic insomnia and sleep maintenance issues.
Panelists discuss how challenges in prescribing subcutaneous infusion systems might affect patient adherence and device management, best practices for patient education, and what additional data would benefit clinicians implementing newer Parkinson disease treatments.
Panelists discuss how 24-hour delivery of continuous subcutaneous infusion therapies impacts nonmotor symptoms and quality of life indicators for patients with Parkinson disease.
A panelist discusses how dual orexin receptor antagonists (DORAs) are effective for treating both sleep initiation and maintenance insomnia, with a generally favorable adverse effect profile, though patients should be informed about potential risks like parasomnia-like behaviors, and the importance of patience and adherence for optimal results.
A panelist discusses how midazolam autoinjectors provide an effective, fast-acting solution for rapid eye seizure termination (REST) in emergency settings, emphasizing the importance of proper education, timely use, and monitoring for adverse effects such as sedation or respiratory depression.
Host Jeffrey Wilken, PhD, chats with Anthony Feinstein, MPhil, PhD, FRCP, about the second day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.
Panelists discuss how physicians can improve outcomes for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) by prioritizing early and accurate diagnosis, personalizing treatment plans, regularly monitoring patients, and addressing the psychological and emotional impact of the disease.
Panelists discuss how recent approvals of novel delivery systems are reshaping the treatment landscape for Parkinson disease by addressing unmet needs in managing motor fluctuations.
Panelists discuss how addressing the unmet needs in chronic inflammatory demyelinating polyneuropathy (CIDP), such as early diagnosis, personalized treatment options, long-term disease management, and improved access to care, could significantly enhance patient outcomes and quality of life.
Panelists discuss how investigational agents, including the complement inhibitor riliprubart, FcRn inhibitors like nipocalimab, batoclimab, and rozanolixizumab, as well as Bruton tyrosine kinase (BTK) inhibitors and anti–myelin-associated glycoprotein (anti-MAG) antibodies, show promise in providing targeted, personalized treatment options for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who are refractory to traditional therapies, with ongoing research needed to confirm their efficacy and safety.
Panelists discuss how their clinical experience with continuous subcutaneous infusion therapies has informed their approach to integrating these treatments into existing regimens, including strategies for medication adjustments and valuable lessons from European clinical practice that could benefit US clinicians.
Host Jeffrey Wilken, PhD, chats with Marie Namey, APRN, MSCN, about the first day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.
Duchenne Muscular Dystrophy progresses with motor delays, varying deterioration rates, and impacts multiple organs, highlighting the need for early intervention.
Explore the comprehensive comorbidities of Duchenne Muscular Dystrophy, including cognitive, respiratory, and nutritional challenges faced by patients.
The pair of neurologists highlight key advances needed in imaging, trial design, and preclinical modeling to drive remyelination breakthroughs in MS.
Duchenne Muscular Dystrophy progresses with motor delays, varying deterioration rates, and impacts multiple organs, highlighting the need for early intervention.
The vice president and franchise lead of Autoimmune at Hansa Biopharma provided clinical insights on latest phase 2 safety and efficacy data on imlifidase, an IgG-cleaving antibody, in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]
In this episode, a duo of neurologists examine the plausibility, limitations, and risks of holistic approaches to remyelination—and what patients should prioritize or avoid.
Panelists Ari Green, MD, and Paul Tesar, PhD, explore the scientific rationale and clinical complexity behind promising remyelination agents currently in development for multiple sclerosis.
Episode 4 covers how aging and disease duration impact remyelination potential and the strategies for targeting repair across the multiple sclerosis spectrum.
In this episode, panelists outline the key scientific and clinical challenges in translating remyelination research into effective therapies for patients with MS.
Neurology News Network. for the week ending May 24, 2025. [WATCH TIME: 4 minutes]
Neurologists Ari Green, MD, and Paul Tesar, PhD, discuss the current limitations of remyelination assessment tools in MS and highlight efforts to develop more reliable clinical measures.
A panelist discusses how managing chronic insomnia often requires tailored treatments like dual orexin receptor antagonists (DORAs), which offer long-term benefits for sleep maintenance without the risk of tolerance or rebound insomnia, while emphasizing patient counseling and realistic expectations for gradual improvement.
Panelists discuss how medical professionals have incorporated continuous subcutaneous infusion systems into their clinical practice.
Panelists discuss how medical professionals view continuous subcutaneous infusion systems for managing Parkinson disease and their evolving role in treatment timing.
A panelist discusses how dual orexin receptor antagonists (DORAs) provide a novel and balanced approach to treating insomnia by targeting orexin receptors to reduce wakefulness without causing the broad central nervous system suppression seen with traditional sleep aids.
The assistant professor of neurology at Robert Wood Johnson Medical School talked about a collaborative initiative that aims to address AD disparities in Asian and Pacific Islander American populations. [WATCH TIME: 3 minutes]
A panelist discusses how the phase 2b ENGAGE-E-001 study highlights Staccato alprazolam as an effective and well-tolerated option for rapid seizure termination, emphasizing its quick onset of action and potential benefits, while also cautioning about adverse effects such as sedation and respiratory depression in certain patients.
In this initial episode, experts Ari Green, MD, and Paul Tesar, PhD, break down the biological foundation and therapeutic importance of remyelination in multiple sclerosis.
